

# Professeur Jacques MOREL

**SERVICE :**  
Rhumatologie

**ÉQUIPE MÉDICALE :**  
Immuno-  
rhumatologie

**FONCTION :**  
PUPH  
Responsable du  
service  
Rhumatologie  
Responsable de  
l'équipe médicale  
Immuno-  
rhumatologie

## CONTACT



**Pr Jacques MOREL**

@ ME CONTACTER

## PRENEZ RENDEZ-VOUS

 Connexion à l'espace professionnel

Service Rhumatologie :

Secrétariat

Courriel

 [Contacter](#)

📞 04 67 33 87 10

Pathologies mécaniques du rachis et des articulations

📞 04 67 33 86 39

Immunologie clinique et thérapeutique

📞 04 67 33 72 31

Secrétariat prise de rdv

📞 04 67 33 72 28

Secrétariat Dr Gaël Mouterde

📞 04 67 33 72 28

Secrétariat Drs Borderie, Boutot, Brun, Cholvy, Nicolas

📞 04 67 33 72 28

Secrétariat Drs Didry, Ferrazzi, Dran Hellier, Legouffe

📞 04 67 33 72 28

Secrétariat Drs Arzac, Oualid, Moulard, Roubille, Vesperini

📞 04 67 33 72 28

Secrétariat Drs Genty, Autuori, Fournet, Roch Bras

📞 04 67 33 72 28

Secrétariat Drs Taboada, Fabre, Fages, Le Blay, Ferreira Lopez

📞 04 67 33 72 31

## PUBLICATIONS



### Ouvrages

**Morel J** et Combe B. Polyarthrite rhumatoïde et « polyarthrites périphériques ». Traité de Médecine Hospitalière. Flammarion ; Paris.

**Morel J**. Pathogénie et clinique de la PR. Lettre du rhumatologue. 2004. 298 : 9-15

**Morel J**, Miossec P, Combe B. Physiopathologie de la PR. Encyclopédie Médico-chirurgicale. 2004.

**Morel J**, Combe : 33 concepts et méthodes qui ont marqué l'évolution de la rhumatologie ces quinze dernières années. Evaluation pronostique initiale de la polyarthrite rhumatoïde. Editions scientifiques LC. Paris. Volume 3. 2005. 7-12

**B Combe et Morel J**. Les anti-TNF dans le traitement des rhumatismes inflammatoires et connectivites. Maladies Systémiques (Flammarion)

### Publications scientifiques

1. **Morel J**, Legouffe MC, Bozonnat MC, Sany J, Eliaou JF, Daurès JP, Combe B.

Outcome in patients with incipient undifferentiated arthritis. *Joint Bone Spine* 2000; 67: 49–53 (AO)

2. Bressolle F, Kinowski JM, **Morel J**, Pouly B, Sany J, and Combe B. Folic acid alters methotrexate availability in patients with rheumatoid arthritis. *Journal of Rheumatology* 2000; 27: 2110–4 (AO)

3. Louis-Plence P, **Morel J\***, Kerlan-Candon S\*, Avinens O, Combe B, Clot J, Eliaou JF and Pinet V. The down regulation of HLA-DM gene expression in rheumatoid arthritis is not related to their promoter polymorphism of the regulatory regions of HLA-DM genes. *Journal of Immunology* 2000; 165: 4861–69. \*The second and third authors contributed equally to the work reported. (AO)

4. **Morel J**, Combe B, Francisco J, Bernard J. Bone density of 720 male sport amateurs involved in different physical activities. *Osteoporosis International* 2001; 12: 152–57 (AO)

5. Ruth JH, Volin MV, Haines GK, III, Woodruff, DC, Katschke KJ, Jr, Woods JM, Park CC, **Morel J**, Koch, AE: Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. *Arthritis Rheumatism* 2001; 44: 1568–81 (AO)

6. **Morel J\***, Park CC\*, Connors MA, Harlow LA, Koch AE: Evidence of IL-18 as a novel angiogenic mediator. *Journal of Immunology* 2001; 167: 1644–53 \* The first two authors contributed equally to the work reported. (AO)

7. **Morel J**, Park CC, Kumar P, Koch AE: Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NF- $\kappa$ B activation. *Laboratory Investigation* 2001; 81: 1371–83 (AO)

8. **Morel J**, Park CC, Woods JM, Koch AE: A novel role for interleukin-18 in adhesion molecule induction through NF- $\kappa$ B and PI<sub>3</sub> kinase dependent signal transduction pathways. *Journal Biological Chemistry* 2001; 276: 37069–75 (AO)

9. **Morel J**, Kumar Pawan, Ruth JH, Park CC, Koch AE: Signaling pathways involved in IL-18-induced VCAM-1 expression in RA synovial fibroblasts. *Journal Biological Chemistry* 2002; 277: 34679–91.(AO)

10. **Morel J**, Da Silva Simoes C, Avinens O, Sany J, Combe B, Eliaou JF. Polymorphism of HLA-DMA and DMB alleles in patients with systemic lupus erythematosus. *Journal of Rheumatology* 2003; 30:1485–90. (AO)

11. Ruth JH, Shahrara S, Kumar P, Park CC, **Morel J**, Katschke KJ Jr, Koch AE: MIP-3 $\rightarrow$  expression in the rheumatoid joint. *Laboratory Investigation* 2003; 81: 1371–83 (AO)

12. **Morel J**, Berenbaum F. Signal transduction pathways : new targets for treating rheumatoid arthritis. *Joint Bone Spine*. 2004 ; 71 : 503–10. (MP)

13. **Morel J**, Roch Bras F, Eliaou JF, Combe B. HLA-DMA\*0103 and DMB\*0104 alleles, as novel prognostic markers in rheumatoid arthritis. *Annals of Rheumatic disease* 2004; 63: 1581–86. (AO)

14. **Morel J**, Combe B. How to predict prognosis in early rheumatoid arthritis? *Best Pract Res Clin Rheumatol*. 2005; 19:137–46 (MP)

15. **Morel J**, Audo R, Hahne M, Combe B. TRAIL induces RA synovial fibroblast proliferation through MAP Kinase and PI3 Kinase. *Journal Biological Chemistry*. 2005; 280: 15709-18 (AO)
16. Pham T, Claudepierre P, Deprez X, Fautrel B, Goupille P, Hilliquin P, Masson C, **Morel J** et al Anti-TNF→ therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammation. *Joint Bone Spine*. 2005 ; 72: S1-58(AO)
17. Gaudreuil S, Jean-Pierre H, **Morel J**. Unusual case of spondylodiscitis due to *Staphylococcus saccharolyticus*. *Joint Bone Spine*. 2005; 72 : 91-92 (letter)
18. Fautrel B, Constantin A, **Morel J** et al. Recommendations of the french society for rheumatology. TNF antagonist therapy in rheumatoid arthritis. *Joint Bone Spine*. 2006; 73 : 433-41 (AO)
19. Lesnik A, Bolivar J, **Morel J**, Taourel P. Pseudotumoral colonic tuberculosis complicating rheumatoid arthritis treated with a tumor necrosis factor antagonist. *AJR Am J Roentgenol*. 2006; 186: 1799-800. (cas clinique)
20. Lukas C, Combe B and **Morel J**. Rheumatoid arthritis: recent advances and perspectives in therapy. *Future in rheumatology*. 2007. 2:143-52 (MP)
21. **Morel J**, Gottenberg JE. Le lymphocyte B: une cible thérapeutique privilégiée dans le traitement de la polyarthrite rhumatoïde. *Revue Rhum*. 2007 ; 74 :732-6 (MP)
22. Audo R, Deschamps V, Hahne M, Combe B and **Morel J**. Apoptosis is not the major death mechanism induced by celecoxib on Rheumatoid Arthritis synovial fibroblasts. *Arthritis Research Therapy*. 2007 ; 9 : R128 (AO)
23. Tavares Figuerredo I, **Morel J** et al. Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis. *Clinical Experimental of Rheumatology*. 2008; 26:18-23 (AO)
24. **Morel J**, Deschamps V, Toussirot E, Pertuiset E, Sordet C, Kieffer X, Sibilia J, Mariette X and Combe B. Characteristics and survival of 26 patients with paraneoplastic arthritis. *Annals Rheumatic Disease*. 2008. 67 : 244-47. (AO)
25. **Morel J**, Roubille C, Deschamps V, Hahne M, and Combe B. Inverse correlation between APRIL and BAFF in systemic lupus. *Ann Rheum Dis*. 2009 ;68: 997-1002.
26. Audo R, Combe B, Coulet B, Hahne M, **Morel J**. The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases. *Cell Death Differ*. 2009;16: 1227-37.
27. Pham T, Fautrel B, Gottenberg JE, Goupille P, Hachulla E, Masson C, **Morel J**, Mouthon L, Saraux A, Schaeffer T, Wendling D, Mariette X, Sibilia J, Rheumatic Diseases & Inflammation Group (Club Rhumatismes et Inflammation, CRI) of the French Society for Rheumatology (Société Française de Rhumatologie, SFR). Rituximab (MabThera) therapy and safety management. Clinical tool guide. *Joint Bone Spine*. 2008;75 Suppl 1:S1-99.
28. Daïen CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, Samimi M, Pavy S, Pertuiset E, Toussirot E, Combe B, **Morel J**; Club Rhumatismes et

Inflammation (CRI). Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. *Rheumatology (Oxford)*. 2009;48:883-6. Review.

29. Ben Abdelghani K, Gerard-Dran D, **Morel J**, Combe B. Clostridium difficile associated reactive arthritis. *Rev Med Interne*. 2010;31:e13-5

30. Pham T, Claudepierre P, Constantin A, Fautrel B, Gossec L, Gottenberg JE, Goupille P, Hachulla E, Masson C, **Morel J**, Saraux A, Schaeffer T, Wendling D, Mariette X, Sibilia J. Abatacept therapy and safety management. *Joint Bone Spine*. 2009 ;76 Suppl 1:S3-S55. Review.

31. Schiffmann A, Pers YM, Lukas C, Combe B, **Morel J**. Mesenteric and splenic cat-scratch disease during etanercept therapy. *Rheumatology (Oxford)*. 2009 ;48:1461-2.

32. Hmamouchi I, Costes V, Combe B, **Morel J**. Scurvy as the presenting illness of Whipple's disease exacerbated by treatment with etanercept in a patient with ankylosing spondylitis. *J Rheumatol*. 2010 ;37(5):1077-8.

33. Hoppé E, Masson C, Audran M, Drillon M, Andreu M, Saraux A, Berthelot JM, Maugars Y, Hmamouchi I, **Morel J**. Whipple's disease diagnosed during biological treatment for joint disease. *Joint Bone Spine*. 2010 ;77(4):335-9.

34. Ben Abdelghani K, Dran DG, Gottenberg JE, **Morel J**, Sibilia J, Combe B. Tumor necrosis factor-alpha blockers in SAPHO syndrome. *J Rheumatol*. 2010 ;37:1699-704

35. Maillefert JF, Puéchal X, Falgarone G, Lizard G, Ornetti P, Solau E, Legré V, Lioté F, Sibilia J, **Morel J**, Maynadié M; Réseau Rhumato Study Group. Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis. *Joint Bone Spine*. 2010

36. Pers YM, Chekroun J, Lukas C, Combe B, **Morel J**. Postoperative discitis due to Propionibacterium acnes. *Presse Med*. 2010

37. Bacconnier L, Combe B, Canaud B, **Morel J**. Efficacy of rituximab in a patient with lupus nephritis despite low levels of CD19. *Rheumatology (Oxford)*. 2010

38. Pham T, Claudepierre P, Constantin A, de Bandt M, Fautrel B, Gossec L, Gottenberg JE, Goupille P, Guillaume S, Hachulla E, Masson C, **Morel J**, Puéchal X, Saraux A, Schaeffer T, Wendling D, Bruckert E, Pol S, Mariette X, Sibilia J. Tocilizumab: therapy and safety management. *Joint Bone Spine*. 2010;77 Suppl 1:S3-100.

39. Calmon-Hamaty F, Combe B, Hahne M, **Morel J**. Lymphotoxin  $\alpha$  stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts. *Cytokine*. 2011;53:207-14.

40. Slimani S, Lukas C, Combe B, **Morel J**. Rituximab in rheumatoid arthritis and the risk of malignancies: Report from a French cohort. *Joint Bone Spine*. 2011;78:484-7.

41. Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, Cuillerier E, Fautrel B, Michelet C, **Morel J**, Puéchal X, Wendling D, Lemann M, Ravaut P, Mariette X; RATIO group. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. *Ann Rheum Dis*. 2011;70:616-23.

42. Meyer A, Chatelus E, Wendling D, Berthelot JM, Dernis E, Houvenagel E, Morel J, Richer O, Schaeffer T, Gottenberg JE, Sibilia J; Club Rhumatisme et Inflammation. Safety and efficacy of anti-tumor necrosis factor  $\alpha$  therapy in ten patients with recent-onset refractory reactive arthritis. *Arthritis Rheum.* 2011;63:1274–80.
43. Audo R, Hamaty FC, Baeten D, Bruyer A, Combe B, Hahne M, **Morel J**. Mechanisms and clinical relevance of TRAIL-triggered responses in synovial fibroblasts of rheumatoid arthritis patients. *Arthritis Rheum.* 2011. 63 : 904–913
44. Calmon-Hamaty F, Combe B, Hahne M, **Morel J**. Lymphotoxin  $\alpha$  revisited: general features and implications in rheumatoid arthritis. *Arthritis Res Ther.* 2011. 26;13:232.
45. Sudre A, Figueredo IT, Lukas C, Combe B, Morel J. On the impact of a dedicated educational program for ankylosing spondylitis: effect on patient satisfaction, disease knowledge and spinal mobility, a pilot study. *Joint Bone Spine.* 2012;79:99–100.
46. Claire Immediato Daien, Yohan Duny, Thomas Barnetche, Jean-Pierre Daurès, Bernard Combe, **J Morel**. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. *Ann Rheum Dis.* 2012; 71:862–8
47. Puéchal X, Gottenberg JE, Berthelot JM, Gossec L, Meyer O, **Morel J**, Wendling D, de Bandt M, Houvenagel E, Jamard B, Lequerré T, Morel G, Richette P, Sellam J, Guillevin L, Mariette X; Investigators of the AutoImmunity Rituximab Registry. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry. *Arthritis Care Res (Hoboken).* 2012 Mar;64(3):331–9. doi: 10.1002/acr.20689.
48. Mouterde G, **Morel J**. Classification criteria for rheumatoid arthritis. *Rev Prat.* 2012;62:1077–80.
49. Le Blay P, Mouterde G, Barnetche T, **Morel J**, Combe B. Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. *J Rheumatol.* 2012; 39:712–5.
50. Le Blay P, Mouterde G, Barnetche T, **Morel J**, Combe B. Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. *Clin Exp Rheumatol.* 2012 ;30:756–64.
51. Ali Ou Alla S, Lukas C, Hajjaj-Hassouni N, Flipo RM, Combe B, **Morel J**. Which treatments had been tapered or stopped in rheumatoid arthritis in long-term DAS28 remission following subcutaneous tumor-necrosis-factor blocker therapy? A retrospective experience on 43 patients. *Joint Bone Spine.* 2012 Mar 27.
52. Bousquet J; Groupe d'étude Clinique Maladies Chroniques Languedoc-Roussillon. [Non-communicable chronic diseases, a global public health priority recognized by the United Nations]. *Presse Med.* 2011;40:787–9.
53. Berthelot JM, De Bandt M, **Morel J**, Benatig F, Constantin A, Gaudin P, Le Loet X,

Maillefert JF, Meyer O, Pham T, Saraux A, Solau-Gervais E, Spitz E, Wendling D, Fautrel B, Guillemin F; STPR group of French Society of Rheumatology. A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: the 'FLARE' instrument. *Ann Rheum Dis.* 2012;71:1110-6.

54. Daïen CI, Fesler P, du Cailar G, Daïen V, Mura T, Dupuy AM, Cristol JP, Ribstein J, Combe B, **Morel J**. Etanercept normalises left ventricular mass in patients with rheumatoid arthritis. *Ann Rheum Dis.* 2013;72:881-7

55. Daïen CI, Daïen V, Parussini E, Dupuy AM, Combe B, **Morel J**. Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study. *J Rheumatol.* 2012; 39:1533-8.

56. Fernandez L, Salinas GF, Rocha C, Carvalho-Pinto CE, Yeremenko N, Papon L, Deckert Valerie, Medema JP, Rovers G, Combe B, **Morel J**, Baeten D, Hahne M. The TNF-family member APRIL dampens collagen-induced arthritis. *Ann Rheum Dis.* 2013;72:1367-74.

57. Goulabchand R, Mouterde G, Barnetche T, Lukas C, **Morel J**, Combe B. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. *Ann Rheum Dis.* 2014 ;73:414-9.

58. **Morel J**, Hahne M. To target or not to target APRIL in systemic lupus erythematosus: that is the question! *Arthritis Res Ther.* 2013;15:107

59. Audo R, Combe B, Hahne M, **Morel J**. The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis. *Cytokine.* 2013;63:81-90

60. Che H, Lukas C, **Morel J**, Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. *Joint Bone Spine.* 2013 Aug 7.

61. Meunier M, Puechal X, Hoppé E, Soubrier M, Dieudé P, Berthelot JM, Caramaschi P, Gottenberg JE, Gossec L, **Morel J**, Maury E, Wipff J, Kahan A, Allanore Y. Rheumatic and musculoskeletal features of Whipple disease: a report of 29 cases. *J Rheumatol.* 2013;40:2061-6

62. Hua C, Barnetche T, Combe B, **Morel J**. Effect of methotrexate, anti-TNF $\alpha$  and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis. *Arthritis Care Res.* 2013 Dec 10.

## PARCOURS



1995 : 2<sup>ème</sup> prix des trois meilleurs abstracts au congrès national de médecine interne (Nice).

1998 : 2<sup>ème</sup> prix des trois meilleurs abstracts au congrès national de rhumatologie

(SFR).

2002 : Prix du meilleur abstract scientifique « Abbott abstract award » au congrès européen de l'EULAR.

2005 : Prix d'excellence de la Fondation pour la Recherche Médicale (Comité Languedoc Roussillon Rouergue). Appel d'offre de la fondation pour la recherche médicale. Subvention pour achat de matériel

## TRAVAUX DE RECHERCHE



Mon activité de recherche clinique et fondamentale s'intéresse aux maladies auto-immunes et en particulier à la polyarthrite rhumatoïde (PR).

Nos deux principales thématiques de recherche sont : **(1)** l'étude des facteurs prédictifs de l'évolution d'une polyarthrite débutante vers la chronicité et la destruction articulaire **(2)** l'étude des cytokines impliquées dans la physiopathologie de la PR dans le but de déterminer de nouvelles cibles thérapeutiques **(3)** identifier des marqueurs de réponse aux médicaments (anti-TNF, tocilizumab etc) **(4)** la prévention des complications liées aux médicaments immuno-modulateurs

## LIENS CONSEILLÉS



Club Rhumatisme et Inflammation (CRI)

Société française de Rhumatologie SFR

Afin de vous proposer du contenu enrichi et d'élaborer des statistiques de fréquentation, nous sommes susceptibles de déposer des cookies tiers sur votre machine. Cela ne peut se faire qu'en obtenant, au préalable, votre consentement pour chacun de ces cookies.

✓ OK, tout  
accepter

Personnaliser